Bird flu: lessons from SARS

Paediatric Respiratory Reviews

Volumn 8, Issue 2, 2007, Pages 171-176

  Wong, Gary W K ^a   Leung, Ting F ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

avian; infection; influenza; SARS

Indexed keywords

ADJUVANT WHOLE VIRION VACCINE; ANTIVIRUS AGENT; CORTICOSTEROID; INACTIVATED SPLIT VIRION VACCINE; INFLUENZA VACCINE; METHYLPREDNISOLONE; OSELTAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; STEROID; UNCLASSIFIED DRUG; ZANAMIVIR;

AVIAN INFLUENZA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; EPIDEMIC; HONG KONG; HUMAN; INFECTION CONTROL; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; THORAX RADIOGRAPHY; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS TRANSMISSION;

HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 34249998439     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2007.04.003     Document Type: Review

References (38)

1. Zhong N.S., and Wong G.W. Epidemiology of severe acute respiratory syndrome (SARS): adults and children. Paediatr Respir Rev 5 (2004) 270-274
2. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_09_19/en/index.html (accessed September 22, 2006).
3. Wong G.W., and Hui D.S. Severe acute respiratory syndrome (SARS): epidemiology, diagnosis and management. Thorax 58 (2003) 558-560
4. Lee N., Hui D., Wu A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003) 1986-1994
5. Wong G.W., and Fok T.F. Severe acute respiratory syndrome (SARS) in children. Pediatr Pulmonol Suppl 26 (2004) 69-71
6. Hon K.L., Leung C.W., Cheng W.T., et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 361 (2003) 1701-1703
7. Wong G.W., Li A.M., Ng P.C., and Fok T.F. Severe acute respiratory syndrome in children. Pediatr Pulmonol 36 (2003) 261-266
8. Beigel J.H., Farrar J., Han A.M., Hayden F.G., et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 353 (2005) 1374-1385
9. Drosten C., Gunther S., Preiser W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003) 1967-1976
10. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003) 1953-1966
11. Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 (2003) 276-278
12. Cheng F.W., Ng P.C., Chiu W.K., et al. A case-control study of SARS versus community acquired pneumonia. Arch Dis Child 90 (2005) 747-749
13. Leung D.T., van Maren W.W., Chan F.K., et al. Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: false seropositivity due to use of bacterially derived antigens. J Virol 80 (2006) 8920-8928
14. Hui D.S., and Wong G.W. Advancements in the battle against severe acute respiratory syndrome. Expert Opin Pharmacother 5 (2004) 1687-1693
15. Leung C.W., and Chiu W.K. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev 5 (2004) 275-288
16. Cheung C.Y., Poon L.L., Lau A.S., et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 360 (2002) 1831-1837
17. Wong C.K., Lam C.W., Wu A.K., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136 (2004) 95-103
18. Cinatl J., Morgenstern B., Bauer G., et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003) 2045-2046
19. Yu W.C., Hui D.S., and Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). Thorax 59 (2004) 643-645
20. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 (2003) 2801-2809
21. Lapinsky S.E., and Granton J.T. Critical care lessons from severe acute respiratory syndrome. Curr Opin Crit Care 10 (2004) 53-58
22. Li A.M., So H.K., Chu W., et al. Radiological and pulmonary function outcomes of children with SARS. Pediatr Pulmonol 38 (2004) 427-433
23. Yu C.C., Li A.M., So R.C., et al. Longer-term follow up of aerobic capacity in children affected by severe acute respiratory syndrome (SARS). Thorax 61 (2006) 240-246
24. Taubenberger J.K., Reid A.H., Lourens R.M., Wang R., Jin G., and Fanning T.G. Characterization of the 1918 influenza virus polymerase genes. Nature 437 (2005) 889-893
25. Yuen K.Y., Chan P.K., Peiris M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 (1998) 467-471
26. Ungchusak K., Auewarakul P., Dowell S.F., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005) 333-340
27. Chan P.K. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 34 (2002) S58-S64
28. Claas E.C., Osterhaus A.D., van Beek R., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 (1998) 472-477
29. Mounts A.W., Kwong H., Izurieta H.S., et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 180 (1999) 505-508
30. Buxton Bridges C., Katz J.M., Seto W.H., et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 181 (2000) 344-348
31. Liem N.T., and Lim W. World Health Organization International Avian Influenza Investigation Team, Vietnam. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis 11 (2005) 210-215
32. Chotpitayasunondh T., Ungchusak K., Hanshaoworakul W., et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11 (2005) 201-209
33. To K.F., Chan P.K., Chan K.F., et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 63 (2001) 242-246
34. Treanor J.J., Hayden F.G., Vrooman P.S., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283 (2000) 1016-1024
35. Cooper N.J., Sutton A.J., Abrams K.R., Wailoo A., Turner D., and Nicholson K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326 (2003) 1235-1239
36. Monto A.S., Fleming D.M., Henry D., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 180 (1999) 254-261
37. Bresson J.-L., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
38. Lin J., Zhang J., Dong X., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997